The 2023 BU CTSI Impact Report

“ We are thrilled to present the 2023 Impact Report from the Boston University Clinical

and Translational Science Institute (BU CTSI). Since receiving initial funding from the National Center for Advancing Translational Sciences in 2008, the BU CTSI has been

a driving force in catalyzing clinical and translational science. The mission of the BU CTSI is to improve health by advancing translational science and research in service of health equity."

David Center, MD - Megan Bair-Merritt, MD, MSCE 

Note: This report highlights the BU CTSI’s achievements throughout

the last calendar year (2023). As we prepare to enter the ninth year of our grant cycle, we anticipate sharing our accomplishments for the grant cycle starting

April 1, 2024 to March 31, 2025.

2024 Research Partnership Scholars Grant

Application due date: Apr. 19, 2024

The BU CTSI's Community Engagement Program is excited to announce the launch of Cycle 3 of our Research Partnership Scholars Grant. This grant provides funding for community and academic researchers to build relationships in preparation for a community engaged research project. See Full RFA Here

TL1 Predoctoral and Postdoctoral Fellowships in Regenerative Medicine

Application due date: Apr. 26, 2024

The BU CTSI will support several predoctoral and postdoctoral fellows as part of the CTSI training program in Regenerative Medicine. Note that open predoctoral and postdoctoral TL1 trainee slots are supported for one year only. See Full RFA Here

R01 Proposal Writing Workshop

Application due date: Apr. 29, 2024

Are you planning on submitting your first R01 proposal to the NIH for the October 7^th, 2024 deadline? Would you benefit from a structured program where you write the Research Strategy component in sections and get feedback along the way?

See Full RFA Here

Notice of Special Interest (NOSI): Women’s Health Research

Application due date: May 6, 2024

This Notice of Special Interest (NOSI) is to highlight interest in receiving research applications focused on diseases and health conditions  that predominantly affect women (e.g., autoimmune diseases, depressive disorders, Alzheimer’s disease and Alzheimer’s disease-related dementias, gender-based violence), present and progress differently in women (e.g., cardiovascular disease, HIV, reproductive aging and its implications), or are female specific (e.g., uterine fibroids, endometriosis, menopause). Learn More

Healing Switch Links Acute Kidney Injury to Fibrosis, Suggesting Way to Protect Kidney Function

The dynamics observed in animal studies may be clinically relevant in people, and treatments targeting Sox9 might promote kidneys to heal instead of scarring. Read More

Experimental Gene Therapy for Giant Axonal Neuropathy Shows Promise in NIH Clinical Trial

Gene therapy uses a modified virus to deliver functional copies of the defective GAN gene to nerve cells in the body. It is the first time a gene therapy has been administered directly into the spinal fluid. Read More

High-Risk, High-Reward Research (HRHR)

The Common Fund’s High-Risk, High-Reward Research program was created to accelerate the pace of biomedical, behavioral, and social science discoveries by supporting exceptionally creative scientists conducting highly innovative research. The program seeks to identify scientists with high-impact ideas that may be risky or at a stage too early to fare well in the traditional peer review process. The program encourages creative, outside-the-box thinkers to pursue exciting and innovative ideas in any area of biomedical, behavioral, or social science within the NIH mission. Learn More